Treatment Type | BRCAm | BRCAwt | Untested | ||||||
---|---|---|---|---|---|---|---|---|---|
n = 15 | % or Range | p-Value | n = 25 | % or Range | p-Value* | n = 128 | % or Range | p-Value** | |
Systemic Treatment | |||||||||
Systemic treatment received, n | 14 | 93.3 % | ref | 23 | 92.0 % | 0.876 | 101 | 78.9 % | 0.138 |
Missing/unknown, n | 1 | 6.7 % | - | 1 | 4.0 % | - | 16 | 12.5 % | - |
Median number of treatment lines (IQR) | 4 (2–4) | 0–6 | ref | 3 (1–5) | 0–11 | 0.832 | 2 (1–3) | 0–6 | 0.001 |
Platinum-containing regimen post-recurrence, n | 13 | 86.7 % | ref | 19 | 76.0 % | 0.404 | 86 | 67.2 % | 0.098 |
Cytoreductive Surgery | |||||||||
Secondary cytoreductive surgery, n | 7 | 46.7 % | ref | 13 | 52.0 % | 0.744 | 52 | 40.6 % | 0.655 |
Missing/unknown, n | 0 | 0.0 % | - | 0 | 0.0 % | - | 5 | 3.9 % | - |
Median months to cytoreductive surgery from recurrence (IQR) | 8.8 (1.5–38.8) | 0–93.5 | ref | 0.8 (−0.4–3.4) | −0.5–11.7 | 0.067 | 0.4 (−0.1–3.4) | −0.8–71.9 | 0.064 |
Radiation Therapy | |||||||||
Radiation therapy, n | 7 | 46.7 % | ref | 9 | 36.0 % | 0.506 | 25 | 19.5 % | 0.027 |
Missing/unknown, n | 0 | 0.0 % | - | 0 | 0.0 % | - | 5 | 3.9 % | - |
Median months to radiation therapy from recurrence (IQR) | 15.8 (7.2–21.9) | 1.7–29.4 | ref | 19.7 (17.0–26.5) | 11.7–34.5 | 0.333 | 3.5 (1.3–11.7) | 0.1–81.5 | 0.109 |
No Treatment (Surgery, Radiation, Systemic), n | 0 | 0.0 % | - | 0 | 0.0 % | - | 3 | 2.3 % | - |
Total Unknown/Missing (Surgery, Radiation, Systemic), n | 0 | 0.0 % | - | 0 | 0.0 % | - | 5 | 3.9 % | - |